leelunsean92
2021-06-18
Hmmm
Dosing underway in BioNTech's Phase 2 trial of mrna-based BNT111 in advanced melanoma
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":166503398,"tweetId":"166503398","gmtCreate":1624015241614,"gmtModify":1631889823306,"author":{"id":3580619001051487,"idStr":"3580619001051487","authorId":3580619001051487,"authorIdStr":"3580619001051487","name":"leelunsean92","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":16,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Hmmm</p></body></html>","htmlText":"<html><head></head><body><p>Hmmm</p></body></html>","text":"Hmmm","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/166503398","repostId":1166489816,"repostType":4,"repost":{"id":"1166489816","kind":"news","pubTimestamp":1624009298,"share":"https://www.laohu8.com/m/news/1166489816?lang=&edition=full","pubTime":"2021-06-18 17:41","market":"us","language":"en","title":"Dosing underway in BioNTech's Phase 2 trial of mrna-based BNT111 in advanced melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1166489816","media":"seekingalpha","summary":"BioNTech(NASDAQ:BNTX)announcesthat the first patient has been treated in its Phase 2 cancer vaccine ","content":"<ul>\n <li>BioNTech(NASDAQ:BNTX)announcesthat the first patient has been treated in its Phase 2 cancer vaccine trial, evaluating the Company’s BNT111in combination with Libtayo (cemiplimab), being co-developed by Regeneron(NASDAQ:REGN)and Sanofi(NASDAQ:SNY)in patients with anti-PD1-refractory/relapsed unresectable Stage III or IV melanoma.</li>\n <li>The trial is enrolling a total of 120 patients. The primary endpoint is the overall response rate (ORR) of BNT111 in combination with Libtayo.</li>\n <li>Secondary endpoints include ORR in the single agent arms, duration of response, and safety.</li>\n <li>The first patient has been dosed in the EU. BioNTech retains global commercial rights to BNT111.</li>\n <li>This Phase 2 clinical trial is based on previous results from the Phase 1 Lipo-MERIT dose escalation trial that demonstrated a favorable safety profile in 89 patients with advanced melanoma.</li>\n <li>The Company also plans to start randomized Phase 2 trials with mRNA vaccine product candidates in two additional programs in 2021 (FixVac: BNT113 and iNeST: BNT122).</li>\n <li>The BNT111-01 trial is being conducted in collaboration with Regeneron.</li>\n <li>BioNTech CEO Ugur Sahin warns of possible COVID resurgence from Delta variant</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dosing underway in BioNTech's Phase 2 trial of mrna-based BNT111 in advanced melanoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDosing underway in BioNTech's Phase 2 trial of mrna-based BNT111 in advanced melanoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 17:41 GMT+8 <a href=https://seekingalpha.com/news/3707553-dosing-underway-in-biontechs-phase-2-trial-of-mrna-based-bnt111-in-advanced-melanoma><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech(NASDAQ:BNTX)announcesthat the first patient has been treated in its Phase 2 cancer vaccine trial, evaluating the Company’s BNT111in combination with Libtayo (cemiplimab), being co-developed ...</p>\n\n<a href=\"https://seekingalpha.com/news/3707553-dosing-underway-in-biontechs-phase-2-trial-of-mrna-based-bnt111-in-advanced-melanoma\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://seekingalpha.com/news/3707553-dosing-underway-in-biontechs-phase-2-trial-of-mrna-based-bnt111-in-advanced-melanoma","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1166489816","content_text":"BioNTech(NASDAQ:BNTX)announcesthat the first patient has been treated in its Phase 2 cancer vaccine trial, evaluating the Company’s BNT111in combination with Libtayo (cemiplimab), being co-developed by Regeneron(NASDAQ:REGN)and Sanofi(NASDAQ:SNY)in patients with anti-PD1-refractory/relapsed unresectable Stage III or IV melanoma.\nThe trial is enrolling a total of 120 patients. The primary endpoint is the overall response rate (ORR) of BNT111 in combination with Libtayo.\nSecondary endpoints include ORR in the single agent arms, duration of response, and safety.\nThe first patient has been dosed in the EU. BioNTech retains global commercial rights to BNT111.\nThis Phase 2 clinical trial is based on previous results from the Phase 1 Lipo-MERIT dose escalation trial that demonstrated a favorable safety profile in 89 patients with advanced melanoma.\nThe Company also plans to start randomized Phase 2 trials with mRNA vaccine product candidates in two additional programs in 2021 (FixVac: BNT113 and iNeST: BNT122).\nThe BNT111-01 trial is being conducted in collaboration with Regeneron.\nBioNTech CEO Ugur Sahin warns of possible COVID resurgence from Delta variant","news_type":1},"isVote":1,"tweetType":1,"viewCount":297,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/166503398"}
精彩评论